koichi seto

Affiliation and department：

Research field (4)： Biological, health, and medical informatics , Molecular biology , Pharmaceuticals - chemistry and drug development , Pharmaceuticals - health and biochemistry

Research theme for competitive and other funds (1)：

2020 - 2023 Examination of the development and effect of an intravenous drip management education program to enhance nursing practice

Papers (30)：

Hidetsugu Fujigaki, Masao Takemura, Michiko Osawa, Aki Sakurai, Kentaro Nakamoto, Koichi Seto, Takashi Fujita, Tadayoshi Hata, Hidehiko Akiyama, Yohei Doi, et al. Reliability of serological tests for COVID-19: comparison of three immunochromatography test kits for SARS-CoV-2 antibodies. Heliyon. 2020. 6. 9. e04929-e04929
Kokichi Katsunuma, Koji Yoshinaga, Yuta Ohira, Runa Eta, Takanori Sato, Takayuki Horii, Takao Tanaka, Mineo Takei, Koichi Seto. Z-100, extracted from Mycobacterium tuberculosis strain Aoyama B, promotes TNF-alpha production via nucleotide-binding oligomerization domain containing 2 (Nod2)-dependent NF-kappa B activation in RAW264.7 cells. MOLECULAR IMMUNOLOGY. 2015. 64. 1. 218-227
Takayuki Horii, Koji Yoshinaga, Nobuyoshi Kobayashi, Koichi Seto, Yuki Orikawa, Masahiro Okamoto, Runa Eta, Yuta Ohira, Kokichi Katsunuma, Yuko Hori, et al. Z-100, an Immunomodulatory Extract of Mycobacterium tuberculosis Strain Aoyama B, Prevents Spontaneous Lymphatic Metastasis of B16-BL6 Melanoma. BIOLOGICAL & PHARMACEUTICAL BULLETIN. 2014. 37. 4. 642-647
Hiroki Kato, Koichi Seto, Nobuyoshi Kobayashi, Koji Yoshinaga, Tim Meyer, Mineo Takei. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells. LIFE SCIENCES. 2011. 89. 17-18. 603-608
Nobuyoshi Kobayashi, Koichi Seto, Takahiro Sasaki, Kokichi Katsunuma, Yuki Orikawa, Makoto Yoshimura, Yoshihiro Shiomi, Yuta Ohira, Minco Takei, Koichiro Tanaka. Acotiamide (Z-338), a Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, Restores Delayed Gastric Emptying Induced by Restraint Stress via the Vagal Afferent Pathway in Rats. GASTROENTEROLOGY. 2011. 140. 5. S603-S603

ｍore...

MISC (18)：

藤垣英嗣, 竹村正男, 大澤道子, 櫻井亜樹, 佐々木俊治, 稲葉正人, 伊藤亮太, 仲本賢太郎, 瀬戸孝一, 藤田孝, et al. イムノクロマト法による血清中抗SARS-CoV-2抗体検出の臨床的有用性. 臨床化学. 2020. 49. Suppl.1. 191-191
藤垣英嗣, 竹村正男, 伊藤亮太, 仲本賢太郎, 瀬戸孝一, 藤田孝, 畑忠善, 秋山秀彦, 斉藤邦明. イムノクロマト法を用いたCOVID-19血清学的診断の有用性の検討. 臨床病理. 2020. 68. 補冊. 266-266
「創薬の新しい潮流を探る-ビッグデータ・AI、創薬モダリティおよび合成生物学の国内動向-」. ヒューマンサイエンス振興財団日本医療研究開発機構研究費(創薬基盤推進研究事業)創薬技術調査報告書(Part 1). 2019
医療分野におけるビッグデータ並びにICT・AIの利活用の最新動向 -創薬並びに個別化医療・先制医療への貢献の道を探る-. ヒューマンサイエンス振興財団日本医療研究開発機構研究費(創薬基盤推進研究事業) 創薬資源調査報告書(平成28年度). 2017
医療ビックデータの活用並びにバイオマーカー実用化の最新動向 -創薬並びに個別化医療や予防医療への可能性を探る-. ヒューマンサイエンス振興財団日本医療研究開発機構研究費(創薬基盤推進研究事業) 創薬資源調査報告書(平成27年度). 2016

ｍore...

Professional career (1)：

薬学博士

Work history (8)：

2024/04 - 現在東京都健康長寿医療センター健康長寿イノベーションセンター産学連携コーディネーター
2024/04 - 現在 Fujita Health University Office for co-innovation & Center for Society Academia Collaboration Professor, Director of Office for Co-innovation, Coordinator
2019/04 - 現在 Fujita Health University Center for Research Promotion and Support
2020/02 - 2024/06 株式会社D&P Labo. 代表取締役社長
2023/02 - 2024/03 Fujita Health University Center for Co-innovation

Show all

Association Membership(s) (6)：

CHEM-BIO INFORMATICS SOCIETY , 日本オミックス医学会 , THE JAPANESE CANCER ASSOCIATION , THE PHARMACEUTICAL SOCIETY OF JAPAN , THE JAPANESE BIOCHEMICAL SOCIETY , THE MOLECULAR BIOLOGY SOCIETY OF JAPAN

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page